Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Core Viewpoint - Outlook Therapeutics has received regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab for treating wet AMD, with financial results for Q3 FY 2024 to be reported on August 14, 2024 [1][3]. Company Overview - Outlook Therapeutics is focused on developing and commercializing ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma) for retinal diseases, including wet AMD [3]. - LYTENAVA™ is the first ophthalmic formulation of bevacizumab to receive marketing authorization from the European Commission and the UK for wet AMD treatment [3]. - The company plans to initiate the commercial launch of LYTENAVA™ in the EU and UK in Q1 2025 [3]. - In the US, ONS-5010/LYTENAVA™ is currently investigational and undergoing a non-inferiority study for wet AMD treatment, with potential plans to resubmit a BLA application to the FDA if successful [3]. Financial Reporting - The company will host a quarterly conference call and live audio webcast on August 14, 2024, at 8:30 AM ET to discuss operational and financial results [1][2].